Gli scienziati dell’Institute of Cancer Research hanno sviluppato un nuovo percorso […]
Search Results for: Trattamento dell'infezione da Helicobacter Pylori
Here's what we've found for you
Treating Patients Who Have Helicobacter pylori Infections
Among other changes, the 2024 version of these guidelines suggests that clinicians use clarithromycin and levofloxacin to treat H. pylori only if susceptibility is proven.
The Impact of Population-Based Helicobacter pylori Test-To-Treat Strategies on Gastric Cancer Outcomes
La migliore soluzione per l’emicrania è rappresentata dai triptani
Per l’emicrania, i triptani, come eletriptan, rizatriptan, sumatriptan e zolmitriptan, sembrano […]
Helicobacter pylori Eradication Treatment Might Help Reduce the Risk of Esophageal Adenocarcinoma
Enhancing Research on Helicobacter pylori Eradication and Esophageal Adenocarcinoma Risk: A Call for Broader Studies and Methodological Rigor
Fibrosi polmonare, Nerandomilast potenziale trattamento orale
Bene lo studio di fase III
Hiv, una iniezione due volte l'anno previene infezione al 96%
I risultati studio di fase III confermano efficacia
Scambia, 'per il tumore di Bianca Balti ottime possibilità di trattamento'
‘In molti casi otteniamo la guarigione, ma la prevenzione è fondamentale’
AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review
The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update (CPU) is to summarize the available evidence and offer expert Best Practice Advice on the integration of potassium-competitive acid blockers (P-CABs) in the clinical management of foregut disorders, specifically including gastroesophageal reflux disease, Helicobacter pylori infection, and peptic ulcer disease.
ACG: linee guida sul trattamento dell’infezione da Helicobacter pylori
L’H.pylori è un batterio che infetta oltre la metà della […]
The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines
Objective
During the last decade, the management of gastric intestinal metaplasia (GIM) has been addressed by several distinct international evidence-based guidelines. In this review, we aimed to synthesise these guidelines and provide clinicians with a global perspective of the current recommendations for managing patients with GIM, as well as highlight evidence gaps that need to be addressed with future research.
Design
We conducted a systematic review of the literature for guidelines and consensus statements published between January 2010 and February 2023 that address the diagnosis and management of GIM.
Results
From 426 manuscripts identified, 16 guidelines were assessed. There was consistency across guidelines regarding the purpose of endoscopic surveillance of GIM, which is to identify prevalent neoplastic lesions and stage gastric preneoplastic conditions. The guidelines also agreed that only patients with high-risk GIM phenotypes (eg, corpus-extended GIM, OLGIM stages III/IV, incomplete GIM subtype), persistent refractory Helicobacter pylori infection or first-degree family history of gastric cancer should undergo regular-interval endoscopic surveillance. In contrast, low-risk phenotypes, which comprise most patients with GIM, do not require surveillance. Not all guidelines are aligned on histological staging systems. If surveillance is indicated, most guidelines recommend a 3-year interval, but there is some variability. All guidelines recommend H. pylori eradication as the only non-endoscopic intervention for gastric cancer prevention, while some offer additional recommendations regarding lifestyle modifications. While most guidelines allude to the importance of high-quality endoscopy for endoscopic surveillance, few detail important metrics apart from stating that a systematic gastric biopsy protocol should be followed. Notably, most guidelines comment on the role of endoscopy for gastric cancer screening and detection of gastric precancerous conditions, but with high heterogeneity, limited guidance regarding implementation, and lack of robust evidence.
Conclusion
Despite heterogeneous populations and practices, international guidelines are generally aligned on the importance of GIM as a precancerous condition and the need for a risk-stratified approach to endoscopic surveillance, as well as H. pylori eradication when present. There is room for harmonisation of guidelines regarding (1) which populations merit index endoscopic screening for gastric cancer and GIM detection/staging; (2) objective metrics for high-quality endoscopy; (3) consensus on the need for histological staging and (4) non-endoscopic interventions for gastric cancer prevention apart from H. pylori eradication alone. Robust studies, ideally in the form of randomised trials, are needed to bridge the ample evidence gaps that exist.
UNVEILING CANCER-RELATED METAPLASTIC CELLS IN BOTH HELICOBACTER PYLORI INFECTION AND AUTOIMMUNE GASTRITIS
Gastric metaplasia may arise as a consequence of chronic inflammation and is associated with an increased risk of gastric cancer development. While Helicobacter pylori (Hp) infection and autoimmune gastritis (AIG) both induce gastric metaplasia, possible distinctions in resulting metaplastic cells and their respective cancer risks requires further investigation.
Linee guida ESC 2024 per la prevenzione e il trattamento dell’ipertensione arteriosa
Questa linea guida della European Society of Cardiology (ESC) presentata a […]
Linee guida ESC 2024 per la gestione della fibrillazione atriale
Le linee guida pratiche della Società Europea di Cardiologia (ESC) […]
Linee guida sull’identificazione e gestione dell’insufficienza surrenalica
Questa linea guida pubblicata da NICE riguarda l’identificazione e la gestione […]